Drugs / NMK89
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06129422 | Oct 2023 → Oct 2025 | malignant pancreatic neoplasm | Nihon Medi-Physics Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-25 | Nihon Medi-Physics Co., Ltd. | Regulatory がんのイメージング剤として開発中の「NMK89」、米国FDAが臨床試験実施申請を受理 nmp.co.jp ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-11 | Nihon Medi-Physics Co., Ltd. | 膵がんのイメージング剤として開発中の「NMK89」、世界初の患者画像撮影を米国で発表 nmp.co.jp ↗ |
| 2022-10-25 | Nihon Medi-Physics Co., Ltd. | がんのイメージング剤として開発中の「NMK89」、米国FDAが臨床試験実施申請を受理 nmp.co.jp ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMK89 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06129422 ↗ |
| Modality | Monoclonal antibody | “anti-human MUC5AC monoclonal antibody” NCT06129422 ↗ |
| Route | Intravenous | “Route of administration: intravenous infusion” NCT06129422 ↗ |
| Target | MUC5AC | “anti-human MUC5AC monoclonal antibody” NCT06129422 ↗ |